Loss-of-function Thr347Ala Variant in the G Protein Subunit-Α11 Causes Familial Hypocalciuric Hypercalcemia 2
- 26 June 2024
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (5) , 1342-1349
Abstract
Context and Objectives To date, only four loss-of-function variants in the GNA11 gene encoding the G protein subunit α11 (Gα11) leading to familial hypocalciuric hypercalcemia 2 (FHH2) have been characterized. Gα11 is involved in calcium-sensing receptor (CaSR) signaling, and loss-of-function variants in GNA11 lead to reduced agonist potency at CaSR and an FHH phenotype. Design and participants We have identified a family with a heterozygous GNA11 Thr347Ala variant and characterized its impact on calcium homeostasis in FHH2 patients and the signaling properties of CaSR through the Gα11-Thr347Ala variant in vitro. Main Outcome Measures The index patient and her family had clinical, biochemical, and genetic analyses performed. The expression levels of Gα11 and the cell-surface expression levels of CaSR in human embryonic kidney 293A Gq/11 knock-out cells (ΔGq/11-HEK293A) co-transfected with CaSR and Gα11 (wild type (WT) or Thr347Ala) were determined, and the functional properties exhibited by calcium at CaSR were characterized in an inositol monophosphate (IP1) accumulation assay. Results Heterozygous carriers of the GNA11 Thr347Ala variant had mild asymptomatic hypercalcemia, hypocalciuria, and inappropriately high normal parathyroid hormone (PTH) levels considering their elevated serum calcium levels. Whereas the variant did not impact Gα11 expression or CaSR cell surface expression levels, calcium displayed a moderately but significantly lower agonist potency at CaSR/Gα11-Thr347Ala-transfected cells compared with CaSR/Gα11-WT-transfected cells in the IP1 accumulation assay (EC50 values of 5.67 mM and 4.38 mM, respectively). Conclusions This identification of a novel GNA11 variant causing FHH2 substantiates the important role of Gα11 for CaSR signaling and Ca2+ homeostasis.Keywords
Funding Information
- Research Fund at Rigshospitalet
- Beckett Foundation
- Novo Nordisk Foundation
- Candy Foundation
- Independent Research Fund Denmark
This publication has 26 references indexed in Scilit:
- GNA11 Variants Identified in Patients with Hypercalcemia or HypocalcemiaJournal of Bone and Mineral Research, 2020
- Familial Hypocalciuric Hypercalcemia Type 1 and Autosomal-Dominant Hypocalcemia Type 1: Prevalence in a Large Healthcare PopulationThe American Journal of Human Genetics, 2020
- Cinacalcet Rectifies Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline Loss-of-Function Gα11 MutationJournal of Bone and Mineral Research, 2017
- Structure–Activity Relationship Studies of the Cyclic Depsipeptide Natural Product YM‐254890, Targeting the Gq ProteinChemMedChem, 2017
- A G-protein Subunit-α11 Loss-of-Function Mutation, Thr54Met, Causes Familial Hypocalciuric Hypercalcemia Type 2 (FHH2)Journal of Bone and Mineral Research, 2016
- Claudin‐14 regulates renal Ca++ transport in response to CaSR signalling via a novel microRNA pathwayThe EMBO Journal, 2012
- Cell signalling diversity of the Gqα family of heterotrimeric G proteinsCellular Signalling, 2006
- Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidismCell, 1993
- Substitution of three amino acids switches receptor specificity of Gqα to that of GiαNature, 1993
- Activation of phospholipase C by the alpha subunits of the Gq and G11 proteins in transfected Cos-7 cells.Journal of Biological Chemistry, 1992